6227 -- Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023 | Poliscope

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

6227

118th Congress

Health

In Committee

Legislative Progress

✓

Introduced

Committee

Floor Vote

Other Chamber

Enacted

Introduced

November 3, 2023

Latest Action

November 10, 2023

Primary Sponsor

David SchweikertRepublican(AZ)

Momentum (last 30 days)

score

0 actions · 0 new cosponsors · 0 votes

Speed vs cohort

65pct

7d open

vs 10,564 other HR bills in the 118th — cohort avg 68d

Summary

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023 This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.

Lobbying filings that explicitly cite this bill (3)

These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.

Filing registrants (1)

TIBER CREEK GROUP (3)

ANIVIVE LIFESCIENCES INC.client→TIBER CREEK GROUP

2024 · first_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Issues related to Valley fever; H.R. 6227/S.3220 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; H.R. 6731/S.3464, the FORWARD Act.

Client expense: Not reported · Firm income: $30,000

H.R. 6227

COREY MALMGREN JOHN GONZALEZ